Feasibility Study of GlaxoSmithKline Biologicals' GSK2202083A Vaccine in Healthy Infants at 3, 5 and 11 Months of Age.

Hepatitis B Clinical Trial

Official title:

Feasibility Study of GlaxoSmithKline Biologicals' GSK2202083A Vaccine in Healthy Infants at 3, 5 and 11 Months of Age.

Clinical Trial Details — Status: Terminated

Administrative data

• NCT number: NCT00871741
• Other study ID #: 111761
• Status: Terminated
• Phase: Phase 2
• Start date: April 1, 2009
• Est. completion date: June 25, 2009

Study information

• Verified date: April 2017
• Source: GlaxoSmithKline
• Contact: n/a
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

This study will evaluate the safety and immunogenicity of GSK Biologicals' GSK2202083A vaccine given as a three-dose vaccination course at 3, 5 and 11 months of age.

Recruitment information / eligibility

• Status: Terminated
• Enrollment: 16
• Est. completion date: June 25, 2009
• Est. primary completion date: June 25, 2009
• Accepts healthy volunteers: Accepts Healthy Volunteers
• Gender: All
• Age group: 8 Weeks to 16 Weeks

Eligibility

Inclusion Criteria:

• A male or female infant between, and including, 8 and 16 weeks at the time of the first vaccination.

• Born after a gestation period of 36 to 42 weeks inclusive.

• Subjects who the investigator believes that their parents/ guardians can and will comply with the requirements of the protocol.

• Written informed consent obtained from the parent or guardian of the subject.

• Healthy subjects as established by medical history and clinical examination before entering into the study.

Exclusion Criteria:

• Use of any investigational or non-registered product other than the study vaccine(s) within 30 days preceding the first dose of study vaccine, or planned use during the study period.

• Chronic administration of immunosuppressants or other immune-modifying drugs since birth.

• Administration of immunoglobulins and/or any blood products since birth or planned administration during the study period.

• Administration of a vaccine not foreseen by the study protocol within 30 days prior to randomisation, or planned administration from randomisation to study Visit 3, or from 30 days before to 30 days after study Visit 4, with the exception of influenza and human rotavirus vaccines. The administration of other vaccines, including conjugated pneumococcal vaccine, is allowed during the period from one day after study Visit 3 to 31 days before study Visit 4.

• Concurrently participating in another clinical study, at any time during the study period, in which the subject has been or will be exposed to an investigational or a non-investigational product

• Evidence of previous or intercurrent diphtheria, tetanus, pertussis, hepatitis B, poliomyelitis, Hib and/or MenC vaccination or disease, including HBV vaccination at birth.

• History of seizures or progressive neurological disease.

• Any confirmed or suspected immunosuppressive or immunodeficient condition, based on medical history and physical examination.

• History of allergic disease or reactions likely to be exacerbated by any component of the vaccine(s).

• Major congenital defects or serious chronic illness.

The following condition is temporary or self-limiting, and a subject may be vaccinated once the condition has resolved if no other exclusion criteria is met:

• Current febrile illness or axillary temperature >= 38.5 ºC or other moderate to severe illness within 24 hours of study vaccine administration

Related Conditions & MeSH terms

• Acellular Pertussis
• Diphtheria
• Haemophilus Influenzae Type b
• Hepatitis B
• Neisseria Meningitidis
• Poliomyelitis
• Tetanus

Intervention

Biological:
• GSK2202083A vaccine
Intramuscular, three doses
• Infanrix hexa
Intramuscular, three doses
• Menjugate
Intramuscular, two doses

Locations

Country	Name	City	State
Slovakia	GSK Investigational Site	Bratislava
Slovakia	GSK Investigational Site	Bratislava
Slovakia	GSK Investigational Site	Dolny Kubin
Slovakia	GSK Investigational Site	Dunajska Streda
Slovakia	GSK Investigational Site	Nove Zamky
Slovakia	GSK Investigational Site	Ruzomberok
Slovakia	GSK Investigational Site	Sturovo
Slovakia	GSK Investigational Site	Trnava

Sponsors (1)

Lead Sponsor	Collaborator
GlaxoSmithKline

Country where clinical trial is conducted

Slovakia, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Anti-PRP Antibody Concentrations = 0.15 mg/mL	As the study was terminated, no blood samples were taken. Hence no immunogenicity analyses were done.	At Month 3
Secondary	Number of Subjects With Any, Grade 3 and Related Solicited Local Symptoms	The solicited local symptoms assessed were pain, redness and swelling. Any = any solicited local symptom irrespective of intensity grade. Grade 3 pain = cried when limb was moved/spontaneously painful. Grade 3 redness/swelling = redness/swelling spreading beyond 20 millimeters (mm) of injection site.; Subjects from Control Group did not receive the second study vaccination dose due to study termination.	During the 8-day (Days 0-7) post-vaccination period following each dose and across doses
Secondary	Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms	The solicited general symptoms assessed were drowsiness, irritability, loss of appetite and temperature.; Any = any general symptom irrespective of intensity grade and relationship to vaccination.; Grade 3 Irritability = crying that could not be comforted/prevented normal activity.; Grade 3 Drowsiness = drowsiness that prevented normal activity. Grade 3 Loss of Appetite = did not eat at all. Related = symptoms assessed by the investigator as causally related to vaccination.; Subjects from Control Group did not receive the second study vaccination dose due to study termination.	During the 8-day (Days 0-7) post-vaccination period following each dose and across doses
Secondary	Number of Subjects With Unsolicited Adverse Events AE(s)	An unsolicited AE covers any untoward medical occurrence in a clinical investigation subject temporally associated with the use of a medicinal product, whether or not considered related to the medicinal product and reported in addition to those solicited during the clinical study and any solicited symptom with onset outside the specified period of follow-up for solicited symptoms. Any was defined as the occurrence of any unsolicited AE regardless of intensity grade or relation to vaccination.	During the 31-day (Days 0-30) post-vaccination period
Secondary	Number of Subjects With Serious Adverse Events (SAEs)	Serious adverse events (SAEs) assessed include medical occurrences that result in death, are life threatening, require hospitalization or prolongation of hospitalization or result in disability/incapacity.	During the entire study period (from Month 0 to Month 9)

External Links

•   Researchers can use this site to request access to anonymised patient level data and/or supporting documents from clinical studies to conduct further research.